New hope for hepatitis c: triple therapy shows promise in untreated patients
NCT ID NCT00780416
First seen Jan 11, 2026 · Last updated Jun 18, 2026 · Updated 22 times
Summary
This study tested a new drug called MP-424 combined with two standard hepatitis C medications (peginterferon alfa-2b and ribavirin) in 189 adults with genotype 1 hepatitis C who had never been treated before. The main goal was to see if the virus could be cleared from the blood 24 weeks after treatment ended. People with severe liver damage or certain mental health conditions were not included.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS C are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Toranomon Hospital
Kawasaki, Takatsu-ku, Japan
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.